STOCK TITAN

[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Alignment Healthcare Chief Medical Officer Hyong (Ken) Kim reported the sale of 18,600 shares of the company’s common stock on 08/13/2025 under a Rule 10b5-1 trading plan adopted on 03/14/2025. The sales generated a weighted-average price of $15.0327 per share, with individual trades executed between $15.00 and $15.09. After the reported transactions, the reporting person beneficially owned 472,167 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses the plan adoption date and the price range for the multiple sales.

Hyong (Ken) Kim, Chief Medical Officer di Alignment Healthcare, ha comunicato la vendita di 18.600 azioni ordinarie della società il 13/08/2025, nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 14/03/2025. Le vendite hanno prodotto un prezzo medio ponderato di 15,0327 USD per azione, con singole operazioni eseguite tra 15,00 e 15,09 USD. Dopo le operazioni riportate, la persona interessata deteneva beneficiariamente 472.167 azioni. Il Modulo 4 è stato firmato da un procuratore per conto della persona che ha presentato la dichiarazione e indica la data di adozione del piano e l'intervallo di prezzo delle vendite multiple.

Hyong (Ken) Kim, Director Médico de Alignment Healthcare, informó la venta de 18.600 acciones ordinarias de la compañía el 13/08/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 14/03/2025. Las ventas generaron un precio medio ponderado de 15,0327 USD por acción, con operaciones individuales ejecutadas entre 15,00 y 15,09 USD. Tras las transacciones notificadas, la persona informante poseía de manera beneficiaria 472.167 acciones. El Formulario 4 fue firmado por un apoderado en nombre del informante y revela la fecha de adopción del plan y el rango de precios de las ventas múltiples.

Alignment Healthcare의 최고의료책임자(Chief Medical Officer) Hyong(겐) Kim은 2025-08-13에 회사 보통주 18,600주를 Rule 10b5-1 거래계획에 따라 매각했다고 보고했습니다. 해당 계획은 2025-03-14에 채택되었습니다. 매각으로 주당 가중평균 가격은 15.0327달러가 되었고, 개별 거래는 15.00달러에서 15.09달러 사이에서 이루어졌습니다. 보고된 거래 이후 보고인은 실질적으로 472,167주를 보유하고 있었습니다. Form 4는 보고인을 대신한 대리인이 서명했으며, 계획 채택일과 다건 매각의 가격 범위를 공개하고 있습니다.

Hyong (Ken) Kim, Chief Medical Officer d'Alignment Healthcare, a déclaré la vente de 18 600 actions ordinaires de la société le 13/08/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 14/03/2025. Les ventes ont généré un prix moyen pondéré de 15,0327 USD par action, avec des transactions individuelles exécutées entre 15,00 et 15,09 USD. Après les opérations signalées, la personne déclarante détenait bénéficiairement 472 167 actions. Le formulaire 4 a été signé par un mandataire pour le compte de la personne déclarante et indique la date d'adoption du plan ainsi que la fourchette de prix des ventes multiples.

Hyong (Ken) Kim, Chief Medical Officer von Alignment Healthcare, meldete den Verkauf von 18.600 Stammaktien des Unternehmens am 13.08.2025 im Rahmen eines am 14.03.2025 eingeführten Rule-10b5-1-Handelsplans. Die Verkäufe ergaben einen gewogenen Durchschnittspreis von 15,0327 USD je Aktie; einzelne Transaktionen lagen zwischen 15,00 und 15,09 USD. Nach den gemeldeten Transaktionen hielt die meldepflichtige Person wirtschaftlich 472.167 Aktien. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet und gibt das Einführungsdatum des Plans sowie die Preisspanne der mehreren Verkäufe an.

Positive
  • Transaction executed under a Rule 10b5-1 plan adopted 03/14/2025, indicating pre-authorized trades
  • Disclosure of weighted-average price and per-share price range ($15.00 to $15.09) with an offer to provide detailed breakdown on request
Negative
  • Disposition of 18,600 shares on 08/13/2025 reduced the reporting person’s holdings
  • Beneficial ownership decreased to 472,167 shares following the reported sale

Insights

TL;DR: Insider sold a small portion of holdings under a pre-established 10b5-1 plan; disclosure is routine and non-material on its face.

The Form 4 shows a planned disposition of 18,600 shares executed on 08/13/2025 under a Rule 10b5-1 plan adopted 03/14/2025. The use of a 10b5-1 plan indicates trades were pre-authorized; the filing reports a weighted-average sale price of $15.0327 and a disclosed per-share price range of $15.00 to $15.09. Post-transaction beneficial ownership stands at 472,167 shares. For most investors this is a routine insider liquidity event rather than a corporate-change signal.

TL;DR: Disclosure meets Section 16 requirements and documents a Rule 10b5-1 plan sale with transparent price-range reporting.

The filing clearly identifies the reporting person’s role as Chief Medical Officer and confirms the transaction was executed pursuant to a 10b5-1 plan adopted 03/14/2025. The reporting includes a weighted-average sale price and a commitment to provide transaction-level pricing if requested, which enhances transparency. The filing is signed by an attorney-in-fact, consistent with permitted representation on Form 4 submissions.

Hyong (Ken) Kim, Chief Medical Officer di Alignment Healthcare, ha comunicato la vendita di 18.600 azioni ordinarie della società il 13/08/2025, nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 14/03/2025. Le vendite hanno prodotto un prezzo medio ponderato di 15,0327 USD per azione, con singole operazioni eseguite tra 15,00 e 15,09 USD. Dopo le operazioni riportate, la persona interessata deteneva beneficiariamente 472.167 azioni. Il Modulo 4 è stato firmato da un procuratore per conto della persona che ha presentato la dichiarazione e indica la data di adozione del piano e l'intervallo di prezzo delle vendite multiple.

Hyong (Ken) Kim, Director Médico de Alignment Healthcare, informó la venta de 18.600 acciones ordinarias de la compañía el 13/08/2025 bajo un plan de negociación Rule 10b5-1 adoptado el 14/03/2025. Las ventas generaron un precio medio ponderado de 15,0327 USD por acción, con operaciones individuales ejecutadas entre 15,00 y 15,09 USD. Tras las transacciones notificadas, la persona informante poseía de manera beneficiaria 472.167 acciones. El Formulario 4 fue firmado por un apoderado en nombre del informante y revela la fecha de adopción del plan y el rango de precios de las ventas múltiples.

Alignment Healthcare의 최고의료책임자(Chief Medical Officer) Hyong(겐) Kim은 2025-08-13에 회사 보통주 18,600주를 Rule 10b5-1 거래계획에 따라 매각했다고 보고했습니다. 해당 계획은 2025-03-14에 채택되었습니다. 매각으로 주당 가중평균 가격은 15.0327달러가 되었고, 개별 거래는 15.00달러에서 15.09달러 사이에서 이루어졌습니다. 보고된 거래 이후 보고인은 실질적으로 472,167주를 보유하고 있었습니다. Form 4는 보고인을 대신한 대리인이 서명했으며, 계획 채택일과 다건 매각의 가격 범위를 공개하고 있습니다.

Hyong (Ken) Kim, Chief Medical Officer d'Alignment Healthcare, a déclaré la vente de 18 600 actions ordinaires de la société le 13/08/2025 dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 14/03/2025. Les ventes ont généré un prix moyen pondéré de 15,0327 USD par action, avec des transactions individuelles exécutées entre 15,00 et 15,09 USD. Après les opérations signalées, la personne déclarante détenait bénéficiairement 472 167 actions. Le formulaire 4 a été signé par un mandataire pour le compte de la personne déclarante et indique la date d'adoption du plan ainsi que la fourchette de prix des ventes multiples.

Hyong (Ken) Kim, Chief Medical Officer von Alignment Healthcare, meldete den Verkauf von 18.600 Stammaktien des Unternehmens am 13.08.2025 im Rahmen eines am 14.03.2025 eingeführten Rule-10b5-1-Handelsplans. Die Verkäufe ergaben einen gewogenen Durchschnittspreis von 15,0327 USD je Aktie; einzelne Transaktionen lagen zwischen 15,00 und 15,09 USD. Nach den gemeldeten Transaktionen hielt die meldepflichtige Person wirtschaftlich 472.167 Aktien. Das Formular 4 wurde von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet und gibt das Einführungsdatum des Plans sowie die Preisspanne der mehreren Verkäufe an.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kim Hyong

(Last) (First) (Middle)
1100 W. TOWN & COUNTRY RD.
SUITE 1600

(Street)
ORANGE CA 92868

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 S(1) 18,600 D $15.0327(2) 472,167 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Date of Rule 10b5-1 plan adoption: 03/14/2025
2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.00 to $15.09. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
Remarks:
/s/ Christopher J. Joyce, as Attorney-in-Fact, for Hyong (Ken) Kim 08/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALHC insider Hyong (Ken) Kim report on Form 4?

The Form 4 reports the sale of 18,600 shares of Alignment Healthcare common stock on 08/13/2025 and shows 472,167 shares beneficially owned after the sale.

Were the sales part of a pre-approved trading plan for ALHC insider transactions?

Yes. The Form 4 states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 03/14/2025.

What price did ALHC shares sell for in this reported transaction?

The filing reports a weighted-average price of $15.0327 per share and discloses individual trade prices ranged from $15.00 to $15.09.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Christopher J. Joyce, as Attorney-in-Fact, on behalf of Hyong (Ken) Kim on 08/15/2025.

Does the Form 4 provide a breakdown of the number of shares sold at each price?

No specific per-trade breakdown is provided in the filing; the reporting person offers to provide full information on request regarding the number of shares sold at each price within the disclosed range.
Alignment Healthcare, Inc.

NASDAQ:ALHC

ALHC Rankings

ALHC Latest News

ALHC Latest SEC Filings

ALHC Stock Data

2.92B
144.64M
4.66%
99.71%
6.7%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
ORANGE